Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castration‐resistant prostate cancer

14 Sept 2011

Abstract excerpt

BACKGROUND: Castration-resistant prostate cancer (CRPC) represents a therapeutic challenge for current medications. METHODS: In order to explore the molecular mechanisms involved in CRPC progression and to identify new therapeutic targets, we analyzed a unique sample set of 11 CRPCs and 7 advanced tumors by array-CGH and gene expression microarrays. The genome-wide DNA and RNA data were integrated to identify...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiovascular, Neuropeptides, and Oxidative Stress Research
Share to Prostate Cancer Diagnosis and Treatment
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21919029
DOI: 10.1002/pros.21487

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castration‐resistant prostate cancerPMID 21919029Read ↗

Targeting PHB1 to inhibit castration-resistant prostate cancer progression in vitro and in vivoSemantic proximity Read ↗

Targeting PHB1 to inhibit castration-resistant prostate cancer progression in vitro and in vivoSemantic proximity Read ↗

lncRNA MAGI2-AS3 suppresses castration-resistant prostate cancer proliferation and migration via the miR-106a-5p/RAB31 axisSemantic proximity Read ↗

Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responsesSemantic proximity Read ↗

Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation TherapySemantic proximity Read ↗

The long noncoding RNA HORAS 5 mediates castration‐resistant prostate cancer survival by activating the androgen receptor transcriptional programSemantic proximity Read ↗

Prevalence and Spectrum of AR Ligand-Binding Domain Mutations Detected in Circulating-Tumor DNA Across Disease States in Men With Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

The mutational landscape of lethal castration-resistant prostate cancer.Semantic proximity Read ↗

Lentiviral vector‐mediated insertional mutagenesis screen identifies genes that influence androgen independent prostate cancer progression and predict clinical outcomeSemantic proximity Read ↗

Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer.Semantic proximity Read ↗

Exploration of the influence of GOLGA8B on prostate cancer progression and resistance of castration-resistant prostate cancer to cabazitaxelSemantic proximity Read ↗

Transcriptome Sequencing Reveals PCAT5 as a Novel ERG-Regulated Long Noncoding RNA in Prostate Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.